Literature DB >> 28435036

Costunolide increases osteoblast differentiation via ATF4-dependent HO-1 expression in C3H10T1/2 cells.

Wan-Jin Jeon1, Kyeong-Min Kim1, Eun-Jung Kim2, Won-Gu Jang3.   

Abstract

AIMS: Costunolide is a sesquiterpene lactones used in many herbal medicines, with well-established anti-inflammatory and anti-oxidant functions modulating endoplasmic reticulum (ER) stress pathways, and which promotes the expression of anti-oxidant genes. The aim of this study is to investigate whether costunolide is involved in osteoblast differentiation and, determine the mechanisms of differentiation in mesenchymal stem cells. MAIN
METHODS: The cytotoxicity of costunolide was identified using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The mRNA and protein expression levels of osteogenic genes were determined by RT-PCR and Western blot analysis. Alkaline phosphate (ALP) staining and Alizarin red S (ARS) staining were performed to evaluate ALP activity and matrix mineralization. Transcriptional activity was detected using a luciferase reporter assay. KEY
FINDINGS: In this study, we determined that costunolide increased the expression of distal-less homeobox 5 (Dlx5), runt-related transcription factor 2 (Runx2), ALP, and osteocalcin (OC) in C3H10T 1/2 cells. Furthermore, costunolide increased ALP activity and matrix mineralization. Interestingly, costunolide increased ER stress by Bip, activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP). However, it did not exert effects on expression of activating transcription factor 6 (ATF6). ATF4 activation has a protective role in oxidative stress, and its transcription induces anti-oxidant genes in cells. Heme oxygenase-1 (HO-1) is a major anti-oxidant enzyme, and is regulated by ATF4. We showed that costunolide treatment increased HO-1 expression. Furthermore, the HO-1 inhibitor, Sn(IV) Protoporphyrin IX dichloride (SnPP) was blocked costunolide-induced Runx2 expression. SIGNIFICANCE: Our results revealed that costunolide-induced osteoblast differentiation is regulated by ATF4-dependent HO-1 expression.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATF4; Costunolide; HO-1; Osteogenesis; SnPP

Mesh:

Substances:

Year:  2017        PMID: 28435036     DOI: 10.1016/j.lfs.2017.04.012

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species.

Authors:  Jiasheng Chen; Binshen Chen; Zhihui Zou; Wei Li; Yiming Zhang; Jinlin Xie; Chunxiao Liu
Journal:  Oncotarget       Date:  2017-11-21

2.  Peroxiredoxin II negatively regulates BMP2-induced osteoblast differentiation and bone formation via PP2A Cα-mediated Smad1/5/9 dephosphorylation.

Authors:  Kyeong-Min Kim; Do-Young Kim; Dong-Seok Lee; Jung-Woo Kim; Jeong-Tae Koh; Eun-Jung Kim; Won-Gu Jang
Journal:  Exp Mol Med       Date:  2019-06-03       Impact factor: 8.718

Review 3.  HO-1 in Bone Biology: Potential Therapeutic Strategies for Osteoporosis.

Authors:  Xueman Zhou; Wenxiu Yuan; Xin Xiong; Zhenzhen Zhang; Jiaqi Liu; Yingcheng Zheng; Jun Wang; Jin Liu
Journal:  Front Cell Dev Biol       Date:  2021-11-30

Review 4.  Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones.

Authors:  Ana Paço; Teresa Brás; Jacqueline O Santos; Paula Sampaio; Andreia C Gomes; Maria F Duarte
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

Review 5.  Sesquiterpene lactones of Aucklandia lappa: Pharmacology, pharmacokinetics, toxicity, and structure-activity relationship.

Authors:  Xin-Nan Liu; Hui-Min Li; Shu-Ping Wang; Jing-Ze Zhang; Dai-Lin Liu
Journal:  Chin Herb Med       Date:  2021-02-16

Review 6.  Bone Health and Natural Products- An Insight.

Authors:  Vasanti Suvarna; Megha Sarkar; Pramila Chaubey; Tabassum Khan; Atul Sherje; Kavitkumar Patel; Bhushan Dravyakar
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.